|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:DAPK1-RBM5 (FusionGDB2 ID:21353) |
Fusion Gene Summary for DAPK1-RBM5 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: DAPK1-RBM5 | Fusion gene ID: 21353 | Hgene | Tgene | Gene symbol | DAPK1 | RBM5 | Gene ID | 1612 | 10181 |
| Gene name | death associated protein kinase 1 | RNA binding motif protein 5 | |
| Synonyms | DAPK|ROCO3 | G15|H37|LUCA-15|LUCA15|RMB5 | |
| Cytomap | 9q21.33 | 3p21.31 | |
| Type of gene | protein-coding | protein-coding | |
| Description | death-associated protein kinase 1DAP kinase 1 | RNA-binding protein 5putative tumor suppressor LUCA15renal carcinoma antigen NY-REN-9 | |
| Modification date | 20200313 | 20200320 | |
| UniProtAcc | P53355 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000358077, ENST00000472284, ENST00000469640, ENST00000408954, ENST00000491893, ENST00000466188, | ENST00000347869, ENST00000469838, ENST00000441812, | |
| Fusion gene scores | * DoF score | 14 X 13 X 5=910 | 8 X 7 X 5=280 |
| # samples | 14 | 8 | |
| ** MAII score | log2(14/910*10)=-2.70043971814109 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: DAPK1 [Title/Abstract] AND RBM5 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | DAPK1(90163342)-RBM5(50145518), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | DAPK1 | GO:0006468 | protein phosphorylation | 10629061 |
| Hgene | DAPK1 | GO:0017148 | negative regulation of translation | 18995835 |
| Hgene | DAPK1 | GO:0035556 | intracellular signal transduction | 10629061 |
| Hgene | DAPK1 | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 16132846 |
| Hgene | DAPK1 | GO:0046777 | protein autophosphorylation | 10629061|12730201 |
| Hgene | DAPK1 | GO:0071346 | cellular response to interferon-gamma | 18995835 |
| Tgene | RBM5 | GO:0000245 | spliceosomal complex assembly | 18951082 |
| Tgene | RBM5 | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 18840686|18951082 |
| Tgene | RBM5 | GO:0043065 | positive regulation of apoptotic process | 18840686 |
| Fusion gene breakpoints across DAPK1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across RBM5 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | BI049651 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
Top |
Fusion Gene ORF analysis for DAPK1-RBM5 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000358077 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000358077 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000358077 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3CDS | ENST00000472284 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000472284 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000472284 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3CDS | ENST00000469640 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000469640 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000469640 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3CDS | ENST00000408954 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000408954 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000408954 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3CDS | ENST00000491893 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000491893 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000491893 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3CDS | ENST00000466188 | ENST00000347869 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-intron | ENST00000466188 | ENST00000469838 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| intron-3UTR | ENST00000466188 | ENST00000441812 | DAPK1 | chr9 | 90163342 | + | RBM5 | chr3 | 50145518 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for DAPK1-RBM5 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for DAPK1-RBM5 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| DAPK1 | . |
| FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing stress fiber formation in endothelial cells. Phosphorylates STX1A and significantly decreases its binding to STXBP1. Phosphorylates PRKD1 and regulates JNK signaling by binding and activating PRKD1 under oxidative stress. Phosphorylates BECN1, reducing its interaction with BCL2 and BCL2L1 and promoting the induction of autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating mTORC1 activity in a growth factor-dependent pathway. Phosphorylates RPS6, MYL9 and DAPK3. Acts as a signaling amplifier of NMDA receptors at extrasynaptic sites for mediating brain damage in stroke. Cerebral ischemia recruits DAPK1 into the NMDA receptor complex and it phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx through NMDA receptor channels, resulting in an irreversible neuronal death. Required together with DAPK3 for phosphorylation of RPL13A upon interferon-gamma activation which is causing RPL13A involvement in transcript-selective translation inhibition.; FUNCTION: Isoform 2 cannot induce apoptosis but can induce membrane blebbing. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for DAPK1-RBM5 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for DAPK1-RBM5 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for DAPK1-RBM5 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | DAPK1 | P53355 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | DAPK1 | P53355 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for DAPK1-RBM5 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | DAPK1 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C0006118 | Brain Neoplasms | 1 | CTD_human |
| Hgene | DAPK1 | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C0007138 | Carcinoma, Transitional Cell | 1 | CTD_human |
| Hgene | DAPK1 | C0009759 | Conjunctival Diseases | 1 | CTD_human |
| Hgene | DAPK1 | C0010606 | Adenoid Cystic Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| Hgene | DAPK1 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Hgene | DAPK1 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| Hgene | DAPK1 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Hgene | DAPK1 | C0035242 | Respiratory Tract Diseases | 1 | CTD_human |
| Hgene | DAPK1 | C0036095 | Salivary Gland Neoplasms | 1 | CTD_human |
| Hgene | DAPK1 | C0085183 | Neoplasms, Second Primary | 1 | CTD_human |
| Hgene | DAPK1 | C0086696 | Neoplasms, Therapy-Associated | 1 | CTD_human |
| Hgene | DAPK1 | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
| Hgene | DAPK1 | C0153633 | Malignant neoplasm of brain | 1 | CTD_human |
| Hgene | DAPK1 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| Hgene | DAPK1 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| Hgene | DAPK1 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| Hgene | DAPK1 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| Hgene | DAPK1 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| Hgene | DAPK1 | C0220636 | Malignant neoplasm of salivary gland | 1 | CTD_human |
| Hgene | DAPK1 | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
| Hgene | DAPK1 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| Hgene | DAPK1 | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| Hgene | DAPK1 | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| Hgene | DAPK1 | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| Hgene | DAPK1 | C0877578 | Treatment related secondary malignancy | 1 | CTD_human |
| Hgene | DAPK1 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| Hgene | DAPK1 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | DAPK1 | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| Hgene | DAPK1 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| Hgene | DAPK1 | C2713368 | Hematopoetic Myelodysplasia | 1 | CTD_human |
| Hgene | DAPK1 | C3463824 | MYELODYSPLASTIC SYNDROME | 1 | CTD_human |
| Hgene | DAPK1 | C3495559 | Juvenile arthritis | 1 | CTD_human |
| Hgene | DAPK1 | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
| Hgene | DAPK1 | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
| Hgene | DAPK1 | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
| Hgene | DAPK1 | C4721453 | Peripheral Nervous System Diseases | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies